Sugi Predict

Sugi Predict / Compounds / SCHEMBL1991966

SCHEMBL1991966

SCHEMBL1991966

CC(=O)NC1(C)CCN(Cc2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 5/20 0.59
▸ DPP4 P27487 1/20 0.57
▸ ALDH1A1 P00352 2/20 0.53
▸ DRD2 P14416 2/20 0.53
▸ OPRL1 P41146 1/20 0.51
▸ CHRM2 P08172 1/20 0.51
▸ CHRM3 P20309 1/20 0.51
▸ CYP3A4 P08684 3/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ DRD4 P21917 1/20 0.50
▸ DRD3 P35462 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ MCHR1 Q99705 1/20 0.49
▸ TSHR P16473 2/20 0.49
▸ SIGMAR1 Q99720 1/20 0.49
▸ USP2 O75604 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HDAC4 P56524 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ HDAC1 Q13547 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8416135 0.99 CYP2D6 (0.58) CYP2D6DPP4ALDH1A1DRD2OPRL1
SCHEMBL17163855 0.92 CYP2D6 (0.53) CYP2D6DPP4ALDH1A1DRD2OPRL1
SCHEMBL953425 0.92 CYP2D6 (0.53) CYP2D6DPP4ALDH1A1DRD2OPRL1
SCHEMBL17082420 0.92 CYP2D6 (0.53) CYP2D6DPP4ALDH1A1DRD2OPRL1
SCHEMBL5149023 0.90 DPP4 (0.58) CYP2D6DPP4ALDH1A1DRD2OPRL1
SCHEMBL4592940 0.86 TNIK (0.50) CYP2D6DPP4ALDH1A1DRD2POLB
SCHEMBL3889270 0.86 CYP2D6 (0.48) CYP2D6DPP4ALDH1A1DRD2OPRL1
SCHEMBL5993260 0.85 DPP4 (0.59) CYP2D6DPP4ALDH1A1DRD2OPRL1
SCHEMBL7502902 0.83 CYP2D6 (0.58) CYP2D6ALDH1A1CYP3A4HSD17B10TSHR
SCHEMBL6543308 0.83 CYP2D6 (0.57) CYP2D6DPP4ALDH1A1OPRL1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-11498896-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2022-11-15 — — US disclosed
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2021-05-20 — — US disclosed
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2021-05-20 — — US disclosed
US-10633336-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2020-04-28 — — US disclosed
US-10633336-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2020-04-28 — — US disclosed
US-5595994-A 1-Halopyrazin- and 1-halopyrimidin-4-amino-4-alkylpiperidines SANOFI (FR) 1997-01-21 — — US disclosed
EP-0739891-A2 Substituted heterocycles ZENECA LIMITED (GB) 1996-10-30 — — EP disclosed
EP-0726893-A1 NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA ZENECA LIMITED (GB) 1996-08-21 — — EP disclosed
US-5534525-A Lactam derivatives ZENECA LIMITED (GB) 1996-07-09 — — US disclosed
US-5502063-A 1-halopyridin-4-amino-4-alkylpiperidines SANOFI (FR) 1996-03-26 — — US disclosed
CN-1106400-A Heteroarylpiperidines, process for their preparation and pharmaceutical compositions in which they are present SANOFI SA (FR) 1995-08-09 — — CN disclosed
WO-1995012577-A1 NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA ZENECA LIMITED (GB) 1995-05-11 — — WO disclosed
EP-0650475-A1 4-AMINO-N --(4-METHYL-4-PIPERIDINYL)-2-METHOXYBENZAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1995-05-03 — — EP disclosed
EP-0647639-A1 Heteroarylpiperidines, process for their preparation and pharmaceutical compositions containing them SANOFI (FR) 1995-04-12 — — EP disclosed
WO-1994002462-A1 4-AMINO-N^_-(4-METHYL-4-PIPERIDINYL)-2-METHOXYBENZAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1994-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11498896-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 CYP2D6 1219/4885DPP4 1080/4885ALDH1A1 1919/4885
US-10633336-B2 Dopamine D2 receptor ligands DRD2, ARRB1, DRD3 CYP2D6 2262/4885DPP4 1556/4885ALDH1A1 2551/4885
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 CYP2D6 1219/4885DPP4 1080/4885ALDH1A1 1919/4885
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 CYP2D6 1219/4885DPP4 1080/4885ALDH1A1 1919/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 CYP2D6 1219/4885DPP4 1080/4885ALDH1A1 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.